Latest Entries »

In Silico Genesis has established a point of contact in the Far East as of April, 2014. Tel/Fax: +82 (0)55 364 1620

Picture inset: Kimberley’s father, Advisor for Operations in the Far East.

Shown below is an executive summary of In Silico Genesis.

In Silico Genesis was founded in early 2011, primarily based on the work carried out in the Laboratory of Molecular Biophysics and the Structural Bioinformatics and Computational Biochemistry Unit, the Department of Biochemistry of the University of Oxford. The Medical Research Council provided the funding for the research and training undertaken, via MRC special training fellowship in Bioinformatics/Neuroinformatics/Health-Informatics, under a project title “Ion channels and their regulatory interactions – a bioinformatics approach”.

In Silico Genesis does a target-driven translation for developing genomic medicine and companion diagnostics. The company has three portfolios in the production line at present, which has been made possible via in kind support provided by the Oxford Supercomputing Centre in the Oxford e Research Centre of the University of Oxford. In Silico Genesis has a target identified for three existing antimalarials in the market (malaria companion diagnostics), an antiviral combination therapy consisting of oligonucleotides and a repurposed drug for influenza A virus (biohazard level 2) and Crimean Congo Haemorrhagic Fever virus (biohazard level 4), and a three-component Alzheimer’s therapy aided by a viral vector for delivery in the brain. The company operates in partnership with the Public Health England for our virus programme and is collaborating with Pharmacology, the University of Oxford for one of our Alzheimer’s projects.

Specialties: Medical genomics, bioinformatics, medical statistics and biochemistry

Kimberley of In Silico Genesis Limited (ISG) is thankful to Dr. Mark Treherne, Chief Executive of UK Trade and Investment (UKTI), Life Science Investment Organisation (LSIO) in Cambridge of England, for his unshakable confidence and trust since the year of foundation of In Silico Genesis.

In Silico Genesis Limited – UN Global Marketplace Vendor ID : 361253

The status of In Silico Genesis Limited with the following UN organizations under UNGM: Successfully registered as shown below, as of 28th of February 2014.

UNGMAsian Development Bank (ADB)
African Development Bank Group (AFDB)
Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO)
Food and Agriculture Organization of the United Nations (FAO)

International Atomic Energy Agency (IAEA)
International Fund for Agricultural Development (IFAD)
International Labour Organization (ILO)
International Trade Centre (ITC)
International Telecommunication Union (ITU)
Organization for the Prohibition of Chemical Weapons (OPCW)
Joint United Nations Programme on HIV/AIDS (UNAIDS)
United Nations Development Programme (UNDP)
United Nations Educational, Scientific and Cultural Organization (UNESCO)
United Nations Population Fund (UNFPA)
Office of the United Nations High Commissioner for Refugees (UNHCR)
United Nations Children’s Fund (UNICEF)
United Nations Office for Project Services (UNOPS)
United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA)
World Health Organization (WHO)
World Intellectual Property Organization (WIPO)
World Meteorological Organization (WMO)

In Silico Genesis signed up a Confidential Disclosure Agreement with ISIS Innovation, the commercial arm of the University of Oxford, and the University of Oxford and plus Baroness Professor Susan Greenfield of Pharmacology of the University of Oxford in June 2013. This 4 way CDA was put in place, following an initial collaborative work with Prof. Greenfield’s lab on a repurposed drug for Alzheimer’s Disease.

In Silico Genesis signed up a Confidential Disclosure Agreement with Public Health England (PHE), previously Health Protection Agency, in June 2013. This CDA was reaffirming an initial CDA placed in October, 2011 between Health Protection Agency (HPA) and In Silico Genesis (ISG) about the antiviral work in collaboration. 

Public Health England (PHE)

In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.


This seminar will look at:

• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future


10.30 – Registration

11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds

11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI

11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics

12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO

12.20 – Q&A with the speakers

12.45 – Networking Lunch

13.45 – Introduction from the Chair
Philip Oliver

13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK

14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences

14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine

14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S

15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne
(then, Williams), In Silico Genesis

15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus

15.30 – Networking drinks

16.30 – Close

Shown above can be found at

An Ion Channel Database – Annotation via Homology Modelling

This is an electronic copy of poster presentation at Cold Spring Harbor Laboratory conference jointed held with the Wellcome Trust Genome Campus in Hinxton, England. It is welcome for anyone to view the work via clicking the link or to download a copy of the digital version of this presentation.

It briefly addresses the construction of genomic database (of ion channel proteins, in this case), which focused particularly on potassium channels and nicotinic acetylcholine receptors. Target sequences of interest can be studied further to understand how they may function biologically, by means of pairwise alignment (2D) and computational models (3D) provided any significant homology detected from the previous alignment.

VF_ISGIn Silico Genesis Ltd presented at Venturefest Oxford 2013, at the request of Oxfordshire Bioscience Network (OBN) to represent the regional biocluster at OBN BioElevator session. This took place in Lecture Theatre 5, SAID Business School of Oxford University on Tuesday, 18th of June, 2013. The session was chaired by the chairman of the Oxfordshire Bioscience Network and attended by the CEO of OBN, Dr. Jon Rees.

In the runner-up to BioTrinity/Venturefest Oxford 2013, In Silico Genesis Limited was also approached by the OBN, about supporting a governmental initiative for the field of Life Sciences in the United Kingdom. In brief, the OBN gave me an opportunity to work with the Office of Life Sciences (OLS). Enclosed is a letter IMG_0001, forwarded to me by the OBN, from the Treasury of Her Majesty’s government. I am thankful to SAID Business School ( of the University of Oxford for having taught me and guided me in this entrepreneurial journey,  during my biochemistry/bioinformatics work undertaken at Oxford. Thank you Oxford for everything you taught me. From Kimberley Treherne, xxx

In Silico Genesis signed up a Confidential Disclosure Agreement with Owen Mumford (, a local manufacturing company based in Woodstock, Oxfordshire in September 2012. This two way CDA was put in place following an initial discussion on a malaria companion diagnostics device.

A closer look at how the digital images are generated.

Upon clicking the link above, you should be able either to view or to download this ppt file, which is simply a poster presentation prepared a while ago for a conference held in Naples, Italy. Hopefully, it may come closer to you how medical genomics can be related to developing good computational models of therapeutic (or scientific) interest, should you get a moment to have a look at this digital version of the poster presentation.

Find us @insilicogenesis at